This venture capital firm with offices in the US is exclusively focused on the AI transformation of healthcare, operating through a physician-centric model that leverages a broad network of medical professionals actively involved in both the investment process and the development of AI solutions, particularly in medical imaging.
The firm invests at the pre-Seed, Seed, and Series A stages, with typical check sizes ranging from $1 million to $2 million. While most investments have been made in U.S.-based companies, the firm remains open to international opportunities, including those in Europe and Asia.
Investment focus is tightly concentrated on disruptive AI-driven technologies in the medical imaging market. The firm does not invest in traditional therapeutics or medical devices, and is currently not considering opportunities outside of AI-centric digital health technologies related to imaging. It is open to investing in companies as early as the pre-prototype stage, provided they are aligned with the firm’s strategic thesis.
The firm seeks to partner with highly driven management teams who possess deep domain expertise across imaging, artificial intelligence, and medical software. While the firm typically co-invests, it maintains an active, hands-on approach, especially through the support of its physician investor network, which helps accelerate product development and clinical relevance.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment